Capacities for theory of mind,metacognition, and neurocognitive function are independently related to emotional recognition in schizophrenia

While many with schizophrenia spectrum disorders experience difficulties understanding the feelings of others, little is known about the psychological antecedents of these deficits. To explore these issues we examined whether deficits in mental state decoding, mental state reasoning and metacognitive capacity predict performance on an emotion recognition task. Participants were 115 adults with a schizophrenia spectrum disorder and 58 adults with substance use disorders but no history of a diagnosis of psychosis who completed the Eyes and Hinting Test. Metacognitive capacity was assessed using the Metacognitive Assessment Scale Abbreviated and emotion recognition was assessed using the Bell Lysaker Emotion Recognition Test. Results revealed that the schizophrenia patients performed more poorly than controls on tests of emotion recognition, mental state decoding, mental state reasoning and metacognition. Lesser capacities for mental state decoding, mental state reasoning and metacognition were all uniquely related emotion recognition within the schizophrenia group even after controlling for neurocognition and symptoms in a stepwise multiple regression. Results suggest that deficits in emotion recognition in schizophrenia may partly result from a combination of impairments in the ability to judge the cognitive and affective states of others and difficulties forming complex representations of self and others.     

Fetal echocardiography for planning perinatal and delivery room care of neonates with congenital heart disease

Fetal echocardiography facilitates the prenatal diagnosis of infants with congenital heart disease (CHD) and through sequential examinations, allows assessment of fetal hemodynamics and cardiovascular status from the time of diagnosis to delivery. Fetal cardiologists have created diagnostic protocols aimed at risk stratifying severity and potential postnatal compromise in fetuses with CHD, and identifying those who may require special intervention at birth or within the first days of life. In this article, we review fetal cardiovascular physiology, the progression of CHD in utero and fetal echocardiographic findings used for risk stratification of newborns with CHD, as well as some of the basic principles of planning for the neonatal resuscitation and initial transitional care of these complex newborns.     

Re‐evaluation of the big blue® mouse assay of propiconazole suggests lack of mutagenicity

Propiconazole (PPZ) is a conazole fungicide that is not mutagenic, clastogenic, or DNA damaging in standard in vitro and in vivo genetic toxicity tests for gene mutations, chromosome aberrations, DNA damage, and cell transformation. However, it was demonstrated to be a male mouse liver carcinogen when administered in food for 24 months only at a concentration of 2,500 ppm that exceeded the maximum tolerated dose based on increased mortality, decreased body weight gain, and the presence of liver necrosis. PPZ was subsequently tested for mutagenicity in the Big Blue® transgenic mouse assay at the 2,500 ppm dose, and the result was reported as positive by Ross et al. ([2009]: Mutagenesis 24:149‐152). Subsets of the mutants from the control and PPZ‐exposed groups were sequenced to determine the mutation spectra and a multivariate clustering analysis method purportedly substantiated the increase in mutant frequency with PPZ (Ross and Leavitt. [2010]: Mutagenesis 25:231‐234). However, as reported here, the results of the analysis of the mutation spectra using a conventional method indicated no treatment‐related differences in the spectra. In this article, we re‐examine the Big Blue® mouse findings with PPZ and conclude that the compound does not act as a mutagen in vivo. © Environ. Mol. Mutagen. 2012. Published 2011 Wiley Periodicals, Inc.     

Using handheld computers for daily alcohol assessment: Results from a pilot study

Aims: The purpose of this pilot study was to determine the feasibility and usability of daily retrospective assessments of alcohol use using handheld computers and to explore their comparability to Timeline Followback (TLFB) assessments.

Methods: College student participants received a Handheld Assessment Tool (HAT) at enrolment, which surveyed alcohol consumption and contextual factors for the previous day. After 1 week of daily monitoring, participants completed a paper‐and‐pencil TLFB assessment and HAT usability scale.

Results: Of the 1,800 matched data points on the HAT and TLFB, the overall level of agreement was very good (kappa = 0.80, p<0.001). The mean difference between the number of drinks per drinking days recorded using both methods was 0.19 (SD = 0.56). Participants completed HAT surveys on 87 out of 91 total possible survey days (95.6%). The HAT recorded 34 drinking days and the TLFB recorded 37 out the 91 possible days; the HAT was reported to be highly usable by all participants.

Conclusion: Overall, the HAT was found to be usable and feasible and produced high adherence. Further research should validate this alcohol assessment approach and apply it to representative populations.